Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398773 · ClinicalTrials.gov registry record · Phase 2
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
A Phase 2 study of HER2/Neu Negative and Progesterone Receptor Negative, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT02398773 is a Phase 2 study of HER2/Neu Negative and Progesterone Receptor Negative that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 99 participants, below the 164-participant average among 28 other HER2/Neu Negative trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02398773, a Phase 2 study of HER2/Neu Negative and Progesterone Receptor Negative, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone estrogen and may "light up" where cancer is in the body. Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help doctors predict how well the cancer will respond to treatment.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- DRUG F-18 16 Alpha-Fluoroestradiol
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- Sidney and Lois Eskenazi Hospital - Indianapolis
- Springmill Medical Center - Indianapolis
Pennsylvania
- Fox Chase Cancer Center - East Norriton Hospital Outpatient Center - East Norriton
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
- Fox Chase Cancer Center - Philadelphia
New York
- Mount Sinai Hospital - New York
- Memorial Sloan Kettering Cancer Center - New York
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Minnesota
- Mayo Clinic in Rochester - Rochester
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02398773
The ClinicalTrials.gov registry entry for NCT02398773 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 28 other HER2/Neu Negative trials with a reported enrollment target (40% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with HER2/Neu Negative appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT02398773 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02398773 about?
NCT02398773 is a clinical study titled "FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy". This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone ...
What is the current status of trial NCT02398773?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2016-05-04. Estimated completion is 2026-03-31.
What conditions does trial NCT02398773 study?
This clinical trial studies the following conditions: HER2/Neu Negative, Progesterone Receptor Negative, Stage IV Breast Cancer AJCC v6 and v7, Progesterone Receptor Positive.
What interventions are being tested in trial NCT02398773?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), F-18 16 Alpha-Fluoroestradiol (DRUG).
Who is sponsoring clinical trial NCT02398773?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02398773 being conducted?
This trial has 20 study locations across Alabama, California, Indiana, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2/Neu Negative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
RECRUITING · Phase 2
-
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.